ICU医疗公司与大冢制药工厂完成合资，加强北美地区静脉输液解决方案的生产与创新-动脉网

ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

CISION 等信源发布 2025-05-01 20:30



可切换为仅中文







The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market.

该合作伙伴关系创建了全球最大的静脉注射溶液生产网络之一，年总产量估计达14亿单位，旨在为北美静脉注射溶液市场带来更多的供应链弹性以及新的创新。

SAN CLEMENTE, Calif.

加利福尼亚州圣克莱门特

and TOKUSHIMA,

和德岛，

Japan

日本

，

May 1, 2025

2025年5月1日

/PRNewswire/ --

ICU Medical, Inc.

ICU医疗公司

(NASDAQ:

（纳斯达克：

ICUI

), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), a subsidiary of Otsuka Holdings Co., Ltd. engaged in the global manufacturing and sale of IV solutions, together announce the formation of

），一家在全球范围内处于领先地位的创新医疗器械的开发、制造和销售商，与大冢制药工厂有限公司（OPF），即隶属于大冢控股有限公司并从事静脉注射溶液的全球制造和销售的子公司，共同宣布达成伙伴关系。

Otsuka ICU Medical LLC

大冢ICU医疗有限责任公司

—a new joint venture aimed at strengthening IV solutions supply chain resiliency and driving innovation in the North American market.

——一家新的合资企业，旨在加强静脉输液供应链的韧性，并推动北美市场的创新。

'We are pleased to have successfully completed the formation of this joint venture with ICU Medical,' said

“我们很高兴成功完成了与ICU Medical的这家合资企业的组建，”表示

Shuichi Takagi

高木秀一

, President and Representative Director of OPF. 'Together, we look forward to bringing innovative IV solutions technologies to the North American market.'

，OPF的总裁兼代表董事。 “我们期待共同将创新的IV解决方案技术带到北美市场。”

Vivek Jain

维韦克·贾恩

, Chief Executive Officer at ICU Medical, commented, 'This partnership will bring additional stability and choice to the North American IV solutions market, and we look forward to providing customers increased economic and clinical value.'

ICU Medical的首席执行官评论道：“此次合作将为北美静脉注射溶液市场带来更多的稳定性和选择，我们期待为客户提供更高的经济和临床价值。”

Otsuka ICU Medical LLC combines OPF's expertise and global manufacturing scale—spanning 16 separate IV solutions production sites across Asia—with ICU Medical's strong North American production in

大冢ICU医疗有限公司结合了OPF的专业知识和全球制造规模——横跨亚洲的16个独立静脉输液溶液生产基地——以及ICU医疗在北美的强大生产能力。

Austin, Texas

德克萨斯州奥斯汀市

. The joint venture will create a valuable offering for North American customers by enhancing global supply resiliency and introducing new PVC-free technologies to the market. Under the terms of the agreement, ICU Medical will provide commercial services for the joint venture to ensure seamless operations for North American customers..

该合资企业将通过增强全球供应链的韧性，并向市场引入新的无PVC技术，为北美客户创造有价值的产品。根据协议条款，ICU Medical将为合资企业提供商业服务，以确保北美客户的无缝运营。

Investor Contacts:

投资者联系方式：

Brian Bonnell

布赖恩·邦内尔

, ICU Medical, Inc.

，ICU医疗公司

949-366-2183

John Mills

约翰·米尔斯

, ICR, Inc.

，ICR公司。

646-277-1254

John.Mills@icrinc.com

约翰·米尔斯@icrinc.com

Media Contact:

媒体联系人：

Harrison Richards

哈里森·理查兹

, ICU Medical, Inc.

，ICU医疗公司

949-366-4261

Harrison.Richards@icumed.com

哈里森.理查兹@icumed.com

About

关于

Otsuka Holdings Co., Ltd.

大塚控股株式会社

：

The corporate philosophy of Otsuka is 'Otsuka-people creating new products for better health worldwide.' The Otsuka group of companies, whose origins date back to 1921, strives daily to achieve the philosophy by creating innovative products, improving human health, and contributing to the lives of people worldwide.

大冢的经营理念是“大冢人创造促进世界健康的新产品”。大冢集团起源于1921年，每天都在通过创新产品、改善人类健康、为世界各地的人们的生活做贡献来实现这一理念。

Otsuka has over 34,000 employees across 168 group companies in 32 countries and regions. .

大冢在32个国家和地区拥有168家集团公司，员工超过34,000人。

About

关于

Otsuka Pharmaceutical Factory, Inc. (OPF)

大冢制药工厂有限公司 (OPF)

：

OPF is the original company from which the Otsuka Group has grown. The management vision of OPF is 'the best partner in clinical nutrition', and as a leading company in clinical nutrition in

OPF是大冢集团成长壮大的原点公司。OPF的经营理念是“临床营养领域的最佳合作伙伴”，作为临床营养领域的领先企业，

Japan

日本

has been developing, manufacturing, and selling IV solutions for over 75 years. Today, in addition to IV solutions, OPF provides a variety of products that contribute to solving issues in the healthcare setting.

已经开发、制造和销售静脉注射溶液超过75年。如今，除了静脉注射溶液外，OPF还提供各种有助于解决医疗环境中问题的产品。

About ICU Medical:

关于ICU医疗：

ICU Medical Inc. (Nasdaq:

ICU医疗公司（纳斯达克：

ICUI

) offers clinically essential medical devices that connect patients and caregivers through life-enhancing, innovative technology, and services that provide meaningful clinical value. The organization's robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, home care, NICU/PICU, oncology, pain management, and respiratory care.

）提供通过增强生命的创新技术和具有重要临床价值的服务来连接患者和护理人员的临床必需医疗设备。该组织的强大产品组合包括用于输液治疗、急诊医学、全身和局部麻醉、家庭护理、新生儿/儿科重症监护室（NICU/PICU）、肿瘤学、疼痛管理和呼吸护理的医疗输送系统和消耗性产品。

More information about ICU Medical Inc. can be found at .

有关ICU医疗公司的更多信息，请访问。

www.icumed.com

。

Cautionary Note on Forward-Looking Statements:

前瞻性声明的注意事项：

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and may often be identified by the use of words such as 'will', 'may', 'could', 'should', 'would,', 'project', 'believe', 'anticipate', 'expect', 'plan', 'estimate', 'forecast', 'potential', 'intend', 'continue', 'target', 'build', 'expand' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the company's expectations, goals or intentions regarding the future, including, but not limited to, the proposed joint venture between the company and Otsuka Pharmaceutical Factory America, Inc.

本新闻稿包含根据修订后的1933年《证券法》第27A条和修订后的1934年《证券交易法》第21E条所定义的前瞻性陈述。这些陈述是依据1995年《私人证券诉讼改革法案》的安全港条款作出的，通常可以通过使用诸如“将”、“可能”、“能够”、“应该”、“会”、“预计”、“相信”、“预期”、“计划”、“估计”、“预测”、“潜力”、“打算”、“继续”、“目标”、“建设”、“扩展”或其否定形式或类似术语来识别，并且可能包括（但不限于）有关公司对未来预期、目标或意图的信息，其中包括但不限于公司与大冢制药美国工厂之间的拟议合资企业。

('Otsuka'), the expected timetable for completing the proposed transaction, benefits and synergies of the proposed transaction, future opportunities for the company and products and any other statements regarding the company's and the proposed joint venture's future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods..

大冢制药，预计完成拟议交易的时间表、拟议交易的收益与协同效应、公司与产品的未来机会，以及任何其他关于公司和拟议合资企业未来运营、预期业务水平、未来收益、计划活动、预期增长、市场机会、战略、竞争和其他对未来期间的期望与目标的陈述。

These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the company and the proposed transaction and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements.

这些前瞻性陈述基于管理层对公司和拟议交易的当前预期、估计、预测和假设，管理层认为这些是合理的，但所有这些都受到风险和不确定性的制约，可能导致实际结果和事件与前瞻性陈述中所述的内容有重大差异。

These risks and uncertainties include, but are not limited to, the parties' ability to consummate the transaction, including Otsuka's ability to terminate the transaction under certain conditions; the regulatory approvals required for the transaction not being obtained, or not being obtained on the terms expected or on the anticipated schedule; the other conditions to the completion of the transaction not being obtained; decreased demand for the products of the company or the proposed joint venture; decreased free cash flow; the inability to recapture conversion delays or part/resource shortages on anticipated timing, or at all; changes in product mix; increased competition from competitors; lack of continued growth or improving efficiencies; unexpected changes in the company's arrangements with its largest customers; the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction; changes in relevant tax and other laws; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards or on an adjusted basis; the completion of the joint venture being more difficult, time-consuming or costly than expected; operating costs, customer loss and business disruption (including, without limit.

这些风险和不确定性包括但不限于：各方完成交易的能力，包括大塚在某些条件下终止交易的能力；交易所需的监管批准未能获得，或未按预期条款或时间表获得；完成交易的其他条件未能满足；对公司或拟议合资企业产品需求的下降；自由现金流减少；无法按预期时间或根本无法弥补转换延迟或部分/资源短缺；产品组合的变化；来自竞争对手的竞争加剧；缺乏持续增长或效率提升；公司与其最大客户之间安排的意外变化；各方达成关于交易时间、完成以及会计和税务处理的预期能力；相关税务及其他法律的变化；财务报表编制过程中使用的估计和判断所涉及的固有不确定性，以及根据GAAP及相关标准或调整后基础提供财务指标估计的不确定性；合资企业的完成比预期更困难、耗时或成本更高；运营成本、客户流失和业务中断（包括但不限于）。

For more detailed information on the risks and uncertainties associated with the company's business activities, see the risks described in the company's Annual Report on Form 10-K for the year ended

有关公司业务活动相关的风险和不确定性的更多详细信息，请参阅公司年度报告表格10-K中描述的风险，截至本年度结束。

December 31, 2023

2023年12月31日

, filed with the Securities and Exchange Commission (the 'SEC') and in any subsequent filings with the SEC. You can access the company's Form 10-K and other filings through the SEC website at

，提交给美国证券交易委员会（“SEC”），并可在之后任何提交给SEC的文件中查阅。您可以通过SEC网站访问该公司的10-K表格及其他文件：

www.sec.gov

, and the company strongly encourages you to do so. The company undertakes no obligation to update any statements herein for revisions or changes after the date of this communication.

，公司强烈鼓励您这样做。本公司不承担在本通讯日期之后对本文中的任何声明进行更新以反映修订或变更的义务。

SOURCE ICU Medical, Inc.

来源：ICU医疗公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers